Skip to main content

Table 4 Association of Her2 and Ki-67 expression with clinicopathologic parameters in patients with non-metastatic gastric cancer

From: Expression and significance of Her2 and Ki-67 in gastric adenocarcinoma without distant metastasis: a cohort study

Variable

 

Double negative, n = 49

Ki-67 positive, n = 91

Her2 positive, n = 21

Double positive, n = 34

χ2/F

Pa

Age (years)

As continuous

63 ± 11; 63 (56–70)

63 ± 8; 65 (59–69)

63 ± 10; 63 (55–71)

66 ± 8; 67 (61–73)

0.70

0.554

Age group

< 60 years

19 (39)

25 (28)

7 (33)

7 (21)

1.98

0.160

 

60–69 years

17 (35)

45 (50)

6 (29)

14 (41)

  
 

≥ 70 years

13 (27)

21 (23)

8 (38)

13 (38)

  

Sex

Male

37 (76)

66 (73)

15 (71)

30 (88)

0.77

0.379

Tumor location

Gastric cardia and fundus

26 (53)

48 (53)

12 (57)

16 (47)

 < 0.01

0.985

 

Gastric body

8 (16)

16 (18)

5 (24)

9 (27)

  
 

Gastric antrum and pylorus

15 (31)

27 (29)

4 (19)

9 (27)

  

Differentiation grade

Well/Moderate

7 (14)

18 (20)

9 (43)

14 (41)

11.01

0.001

 

Poor/undifferentiated

42 (86)

73 (80)

12 (57)

20 (59)

  

Neural invasion

Yes

10 (20)

12 (13)

6 (29)

7 (21)

0.44

0.506

Cancer embolus

Yes

10 (20)

20 (22)

4 (19)

5 (15)

0.12

0.733

Tumor length (cm)

As continuous

5.1 ± 2.1; 5.0 (3.5–6.5)

4.8 ± 2.3; 4.5 (3.0–6.0)

4.7 ± 2.6; 4.0 (3.0–5.0)

4.4 ± 2.1; 4.0 (2.8–5.5)

0.59

0.625

Tumor width (cm)

As continuous

4.0 ± 1.6; 4.0 (2.5–5.0)

3.8 ± 1.9; 3.5 (2.5–5.0)

3.6 ± 2.0; 3.0 (2.8–4.5)

3.3 ± 1.5; 3.0 (2.5–4.0)

0.84

0.474

Metastatic lymph node

As continuous

4 ± 5; 3 (0–7)

4 ± 5; 2 (0–7)

3 ± 5; 1 (0–6)

3 ± 4; 2 (0–5)

0.50

0.683

Lymph node ratio

As continuous

0.22 ± 0.23; 0.18 (0.00–0.32)

0.20 ± 0.25; 0.09 (0.00–0.35)

0.18 ± 0.26; 0.05 (0.00–0.28)

0.19 ± 0.24; 0.11 (0.00–0.27)

0.16

0.921

pT stage

1

2 (4)

11 (12)

3 (14)

4 (12)

6.88

0.009

 

2

1 (2)

10 (11)

4 (19)

8 (24)

  
 

3–4

46 (94)

70 (77)

14 (67)

22 (65)

  

pN stage

0

16 (33)

33 (36)

9 (43)

12 (35)

0.52

0.472

 

1

7 (14)

16 (18)

5 (24)

6 (18)

  
 

2

13 (27)

19 (21)

2 (10)

9 (26)

  
 

3

13 (27)

23 (25)

5 (24)

7 (21)

  

pTNM stage

I

2 (4)

18 (20)

5 (24)

6 (18)

5.24

0.022

 

II

13 (27)

18 (20)

6 (29)

12 (35)

  
 

III

34 (69)

55 (60)

10 (48)

16 (47)

  
  1. Categorical data are shown as count (percentage [%]), and continuous data as mean ± standard deviation; median (interquartile range)
  2. pTNM stage pathological tumor-node-metastasis stage, Her2 human epidermal growth factor receptor 2
  3. aFor comparison across groups
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us